BR112023000669A2 - Inserto ocular contendo um glicocorticoide - Google Patents

Inserto ocular contendo um glicocorticoide

Info

Publication number
BR112023000669A2
BR112023000669A2 BR112023000669A BR112023000669A BR112023000669A2 BR 112023000669 A2 BR112023000669 A2 BR 112023000669A2 BR 112023000669 A BR112023000669 A BR 112023000669A BR 112023000669 A BR112023000669 A BR 112023000669A BR 112023000669 A2 BR112023000669 A2 BR 112023000669A2
Authority
BR
Brazil
Prior art keywords
glucocorticoid
insert containing
ocular insert
ocular
intracanalicular
Prior art date
Application number
BR112023000669A
Other languages
English (en)
Inventor
D Blizzard Charles
Desai Ankita
Goldstein Michael
Original Assignee
Ocular Therapeutix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ocular Therapeutix Inc filed Critical Ocular Therapeutix Inc
Publication of BR112023000669A2 publication Critical patent/BR112023000669A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

INSERTO OCULAR CONTENDO UM GLICOCORTICOIDE. A presente invenção refere-se, em certas modalidades, a um inserto intracanalicular biodegradável de liberação sustentada que contém um glicocorticoide disperso em um hidrogel para o tratamento de doença do olho seco.
BR112023000669A 2020-07-16 2021-07-15 Inserto ocular contendo um glicocorticoide BR112023000669A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063052646P 2020-07-16 2020-07-16
US202063124176P 2020-12-11 2020-12-11
US202163181720P 2021-04-29 2021-04-29
PCT/US2021/041761 WO2022015940A1 (en) 2020-07-16 2021-07-15 Ocular insert containing a glucocorticoid

Publications (1)

Publication Number Publication Date
BR112023000669A2 true BR112023000669A2 (pt) 2023-04-25

Family

ID=77300995

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023000669A BR112023000669A2 (pt) 2020-07-16 2021-07-15 Inserto ocular contendo um glicocorticoide

Country Status (10)

Country Link
EP (1) EP4181930A1 (pt)
JP (1) JP2023534952A (pt)
KR (1) KR20230041708A (pt)
CN (1) CN116133664A (pt)
AU (1) AU2021309965A1 (pt)
BR (1) BR112023000669A2 (pt)
CA (1) CA3174217A1 (pt)
IL (1) IL299769A (pt)
MX (1) MX2023000628A (pt)
WO (1) WO2022015940A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009000760A (es) 2006-07-20 2009-02-05 Sicor Inc Proceso para la preparacion de ingrediente farmaceutico activo esteril solido.
EP2156823A1 (en) 2008-08-14 2010-02-24 Pharmatex Italia Srl Process for the preparation of sterile powdered pharmeceutical compounds in the form of micro and nanoparticles
CA2750242C (en) * 2009-02-12 2018-05-22 Incept, Llc Drug delivery through hydrogel plugs
EP4279064A3 (en) 2015-05-12 2024-02-28 Incept, LLC Drug delivery from hydrogels
CA3038075A1 (en) * 2016-09-23 2018-03-29 Incept, Llc Intracameral drug delivery depots

Also Published As

Publication number Publication date
CA3174217A1 (en) 2022-01-20
MX2023000628A (es) 2023-02-27
AU2021309965A1 (en) 2023-02-23
CN116133664A (zh) 2023-05-16
EP4181930A1 (en) 2023-05-24
WO2022015940A1 (en) 2022-01-20
IL299769A (en) 2023-03-01
JP2023534952A (ja) 2023-08-15
KR20230041708A (ko) 2023-03-24

Similar Documents

Publication Publication Date Title
BR112018074389A2 (pt) envio de fármaco intraocular
CL2016002812A1 (es) Uso de ácido 3-2,3,5,6-tetrafluoro-3-trifluorometoxi-bifenil-4-ilcarbamoil-tiofeno-2-carboxílico para preparar un medicamento útil para tratar una enfermedad ocular que es uveítis, ojo seco o causada por un adenovirus composición formulación.
BR112018074454A2 (pt) composições e métodos de uso de nintedanib para tratar doenças oculares com neovascularização anormal
BRPI0520014A2 (pt) emulsões oftálmicas estáveis de óleo-em-água com hialuronato de sódio para alìvio de olho seco
BR112017004679A2 (pt) dispositivos, sistemas e métodos de fototerapia com múltiplos comprimentos de onda para o tratamento não invasivo de tecido danificado ou doente
GT201400036A (es) Compuestos y composiciones como inhibidores de la quinasa c - kit
UY30058A1 (es) (indazol-5-il)-piracinas y (1,3-dihidro-indol-2-on)-piracinas para el tratamiento de enfermedades y afecciones mediadas por la rho quinasa
CR20140476A (es) Agentes para tratar transtornos que implican la modulación de receptores de rianodina
CL2022002606A1 (es) Implante ocular que contiene un inhibidor de la tirosina cinasa
BR112014010376A2 (pt) medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima
CO2017005624A2 (es) Composiciones oftálmicas estabilizadas de omega 3
WO2014145666A3 (en) Treatments of extracellular matrices of the eye
BR112021019774A2 (pt) Insertos oculares poliméricos dissolvíveis e método para usar os mesmos
CL2020003008A1 (es) Estimulador de treg selectivo rur20kd-il-2 y composiciones relacionadas
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
BR112012028437A2 (pt) solução oftálmica, e, método para tratar glaucoma ou hipertensão ocular
BR112018012927A2 (pt) reguladores cftr e métodos de uso dos mesmos
UY32758A (es) Composiciones y métodos para el tratamiento de infecciones ópticas, nasales u oftálmicas
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
BR112017004903A2 (pt) composições para fibras de queratina
CO2021015265A2 (es) Composiciones y métodos de oximetazolina para el tratamiento de trastornos oculares
BR112017015528A2 (pt) processo para produção de um implante e implante
CO2023005996A2 (es) Composiciones y métodos para el tratamiento de la enfermedad ocular tiroidea
BR112023000669A2 (pt) Inserto ocular contendo um glicocorticoide
MX2023004614A (es) Implante ocular que contiene un agente activo.